Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation
- PMID: 40564141
- PMCID: PMC12191254
- DOI: 10.3390/biomedicines13061422
Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a global health burden, however, therapeutic advancements remain hindered by incomplete insights on mechanisms and suboptimal clinical interventions. This review focused on the transcription factors (TFs) associated with the gut-liver axis, emphasizing their roles as molecular interpreters of systemic crosstalk in MAFLD. We delineate how TF networks integrate metabolic, immune, and gut microbial signals to manage hepatic steatosis, inflammation, and fibrosis. For instance, metabolic TFs such as peroxisome proliferator-activated receptor α (PPARα) and farnesoid X receptor (FXR) are responsible for regulating lipid oxidation and bile acid homeostasis, while immune-related TFs like signal transducer and activator of transcription 3 (STAT3) modulate inflammatory cascades involving immune cells. Emerging evidence highlights microbiota-responsive TFs, like hypoxia-inducible factor 2α (HIF2α) and aryl hydrocarbon receptor (AHR), linking microbial metabolite signaling to hepatic metabolic reprogramming. Critically, TF-centric therapeutic strategies, including selective TF-agonists, small molecules targeted to degrade TF, and microbiota modulation, hold considerable promise for treating MAFLD. By synthesizing these insights, this review underscores the necessity to dissect TF-mediated interorgan communication and proposes a roadmap for translating mechanism discoveries into precision therapies. Future research should prioritize the use of multi-omics approaches to map TF interactions and validate their clinical relevance to MAFLD.
Keywords: inflammation; metabolic dysfunction-associated fatty liver disease; metabolism; microbiota; molecular mechanisms; transcription factors.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Multiomics reveals metformin's dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention.Sci Rep. 2025 Jul 2;15(1):22699. doi: 10.1038/s41598-025-07557-7. Sci Rep. 2025. PMID: 40594788 Free PMC article.
-
Lactobacillus plantarum 1-2-3 inhibits ferroptosis by regulating dysregulated fatty acid metabolism to protect mice from high-fat diet-induced MAFLD.Free Radic Biol Med. 2025 Oct;238:137-151. doi: 10.1016/j.freeradbiomed.2025.06.042. Epub 2025 Jun 22. Free Radic Biol Med. 2025. PMID: 40555343
-
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.Int J Mol Sci. 2025 Jun 7;26(12):5486. doi: 10.3390/ijms26125486. Int J Mol Sci. 2025. PMID: 40564947 Free PMC article. Review.
-
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease.Front Pharmacol. 2025 Jun 10;16:1600439. doi: 10.3389/fphar.2025.1600439. eCollection 2025. Front Pharmacol. 2025. PMID: 40556760 Free PMC article. Review.
-
Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo.Br J Dermatol. 2025 Jun 20;193(1):115-124. doi: 10.1093/bjd/ljaf041. Br J Dermatol. 2025. PMID: 39888372
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous